Coya Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA on COYA101 for the Treatment of Amyotrophic Lateral Sclerosis
Plans to submit an IND to support a Phase 2b clinical trial for COYA101 HOUSTON,…
Month: November 2021
SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences
SOTIO Biotech licenses LegoChem Biosciences (LCB) technology for five new antibody-drug conjugate (ADC) programs Rights…
Erasca to Present at the Evercore ISI 4th Annual HealthCONx Conference
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision…
BetterLife Obtains TD-0148A Behavioural Pharmacology Data Confirming its Projected Non-hallucinogenic Property
VANCOUVER, British Columbia, Nov. 16, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
Reflect Scientific Inc. Releases Third Quarter 2021 Financials
OREM, Utah., Nov. 16, 2021 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (OTCQB: RSCF), a provider…
Vaxart Announces Publication of Complete Data from Preclinical COVID-19 Oral Vaccine Hamster Challenge Study in Journal of Infectious Diseases
Study demonstrates oral vaccination significantly reduces viral titers in the lung and protects against COVID-19…
Takeda’s Area Offices in Dubai, United Arab Emirates Certified Sustainable and Inaugurated
Takeda Pharmaceuticals Company (“Takeda”), a global, values-based, R&D-driven biopharmaceutical company, hosted the formal inauguration of…
Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference
NEW YORK and CLEVELAND, Nov. 16, 2021 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO),…
Mydecine Reports Third Quarter 2021 Financial Results and Provides Business Update
—To Launch Phase 2/3 Smoking Cessation Clinical Trial with Johns Hopkins University (JHU) Signed 5-Year…
Otonomy to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated…
Tilray to Webcast Annual Meeting of Stockholders on November 22, 2021
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) — Tilray, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY),…
Humacyte Presents Preclinical Results of Small-Diameter HAV™ for Use as a BTT Shunt in Pediatric Heart Disease at American Heart Association’s Scientific Sessions 2021
— Patency and host cell remodeling of the HAV were observed in all study implants…
Genenta To Present Updated Phase I/II Data At Upcoming Scientific Congresses SNO AND ASH
MILAN, Italy and NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) — Genenta Science, a clinical-stage biotechnology…
Clearside Biomedical Features FDA-Approved XIPERE™ in Multiple Presentations at the American Academy of Ophthalmology 2021 and American Uveitis Society Meetings
Investigational therapeutics injected via the SCS Microinjector® demonstrate positive clinical data in wet AMD, diabetic…
Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update
Interim data update at SITC for ongoing ACTengine® IMA203 trial targeting PRAME demonstrated clinical responses…
Voyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene…
Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia
Positive trend observed in transfusion-dependent subjects treated with higher dose tovinontrine for reduced transfusion burden Tovinontrine…
ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC
ADMA Now Collects Plasma from Six Vertically Integrated Centers with Three Additional Facilities Under Construction…
AIM ImmunoTech Provides Third Quarter 2021 Business Update
OCALA, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) announces…
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at the American Heart Association Scientific Sessions 2021
VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce total ischemic events by 32%…